About Repligen Corporation
Ticker
info
RGEN
Trading on
info
NASDAQ
ISIN
info
US7599161095
Industry
info
Medical Instruments & Supplies
Sector
info
Healthcare
CEO
info
Olivier Loeillot
Headquarters
info
Building 1, Waltham, MA, United States, 02453
Employees
info
1,778
Website
info
repligen.com
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$8.13B
P/E ratio
info
-
EPS
info
-$0.46
Dividend Yield
info
0.00%
Beta
info
1.27
Forward P/E ratio
info
84.03
EBIDTA
info
$107M
Ex dividend date
info
-
Price & volume
Market cap
info
$8.13B
Average daily volume
info
0.9M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
84.03
PEG ratio
info
2.59
Trailing P/E
info
0
Price to sales
info
12.82
Price to book
info
4.12
Earnings
EPS
info
-$0.46
EPS estimate (current quarter)
info
$0.41
EPS estimate (next quarter)
info
$0.37
EBITDA
info
$107M
Revenues (TTM)
info
$634M
Revenues per share (TTM)
info
$11.34
Technicals
Beta
info
1.27
52-week High
info
$182.52
52-week Low
info
$102.97
50-day moving average
info
$141.31
200-day moving average
info
$145.82
Short ratio
info
4.85
Short %
info
8.50%
Management effectiveness
ROE (TTM)
info
1.30%
ROA (TTM)
info
0.83%
Profit margin
info
4.02%
Gross profit margin
info
$319M
Operating margin
info
18.33%
Growth
Quarterly earnings growth (YoY)
info
83.00%
Quarterly revenue growth (YoY)
info
0.60%
Share stats
Outstanding Shares
info
56.2M
Float
info
52.5M
Insiders %
info
6.44%
Institutions %
info
103.64%
Analyst Insights & forecasts
info

71% Buy

29% Hold

0% Sell

Based on information from 17 analysts.

Average price target

info
$187.60
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.28
$0.30
6.67%
Q1 • 24Beat
$0.33
$0.33
-
Q2 • 24Beat
-$0.01
$0.33
103.55%
Q3 • 24Beat
$0.44
$0.42
4.99%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$155M
$-0.7M
0.42%
Q3 • 24
$168M
$-33.9M
20.21%
Q4 • 24
8.18%
5,078.75%
4,686.94%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$2.83B
$814M
28.76%
Q3 • 24
$2.83B
$857M
30.28%
Q4 • 24
0.03%
5.28%
5.32%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$49.3M
$-5.9M
$-69.6M
$42.2M
Q3 • 24
$39.2M
$-64.8M
$1.4M
$29.2M
Q4 • 24
20.57%
1,005.34%
102.08%
30.82%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Repligen Corporation share?
Collapse

Repligen Corporation shares are currently traded for undefined per share.

How many shares does Repligen Corporation have?
Collapse

Repligen Corporation currently has 56.2M shares.

Does Repligen Corporation pay dividends?
Collapse

No, Repligen Corporation doesn't pay dividends.

What is Repligen Corporation 52 week high?
Collapse

Repligen Corporation 52 week high is $182.52.

What is Repligen Corporation 52 week low?
Collapse

Repligen Corporation 52 week low is $102.97.

What is the 200-day moving average of Repligen Corporation?
Collapse

Repligen Corporation 200-day moving average is $145.82.

Who is Repligen Corporation CEO?
Collapse

The CEO of Repligen Corporation is Olivier Loeillot.

How many employees Repligen Corporation has?
Collapse

Repligen Corporation has 1,778 employees.

What is the market cap of Repligen Corporation?
Collapse

The market cap of Repligen Corporation is $8.13B.

What is the P/E of Repligen Corporation?
Collapse

The current P/E of Repligen Corporation is null.

What is the EPS of Repligen Corporation?
Collapse

The EPS of Repligen Corporation is -$0.46.

What is the PEG Ratio of Repligen Corporation?
Collapse

The PEG Ratio of Repligen Corporation is 2.59.

What do analysts say about Repligen Corporation?
Collapse

According to the analysts Repligen Corporation is considered a buy.